Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy In Vitro and In Vivo
Figure 3
Growth curves showed the proliferation of MHCC97H cells until 72 h by CCK-8 assay. NET-1shRNA, sorafenib, and combination of NET-1shRNA with sorafenib resulted in 14.6%, 19.3%, and 33.3% reduction of cell proliferation at 48 h, in 46.5%, 50.6%, and 66.3% reduction of cell proliferation at 72 h. (● compared with untreated group. * compared with combination group).
